Clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer

LI Hongzhi; WANG Honggang

doi:10.7619/jcmp.201923015

Journal of Clinical Medicine in Practice > 2019 > 23(23): 51-54. > DOI: 10.7619/jcmp.201923015

LI Hongzhi, WANG Honggang. Clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer[J]. Journal of Clinical Medicine in Practice, 2019, 23(23): 51-54. DOI: 10.7619/jcmp.201923015

Citation:

PDF (561 KB)

Clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer

LI Hongzhi¹,
WANG Honggang²

1.
Department of Oncology, Taizhou People′s Hospital, Taizhou, Jiangsu, 225300
2.
Department of Intestinal Surgery, Taizhou People′s Hospital, Taizhou, Jiangsu, 225300

More Information

Received Date: October 11, 2019
Available Online: February 28, 2021
Published Date: December 14, 2019

Graphical Abstract

Abstract

Abstract

Objective To explore the clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer.
Methods Seventy patients with medium to advanced rectal cancer were randomly divided into two groups, with 35 cases in each group. The control group was treated with preoperative concurrent chemoradiotherapy by capecitabine, and the observation group received oxaliplatin plus capecitabine for preoperative concurrent chemoradiotherapy. Both groups were followed up for 12 months, and the clinical effects were observed in two groups.
Results The total effective rate was 82.86% in the observation group, which was significantly higher than 57.14% in the control group (P < 0.05). The local recurrence rate within 1 year after operation in the observation group was 20.00%, which was significantly lower than 42.86% in the control group (P < 0.05). The survival rate was 82.86% in the observation group, which was significantly higher than 60.00% in the control group (P < 0.05). In the comparison of quality of life, the scores of the four dimensions such as physiological, psychological, social and environmental abilities in the observation group were significantly higher than the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The distant metastasis rate of the observation group and the control group within 1 year was 14.29% and 31.43%, respectively (P>0.05).
Conclusion Preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine is effective in the treatment of medium to advanced rectal cancer, which can significantly reduce the local recurrence rate and improve the quality of life.
- concurrent chemoradiotherapy,
- medium to advanced rectal cancer,
- oxaliplatin,
- capecitabine,
- recurrence rate,
- efficacy

FullText(HTML)

References (16)

References

[1]	林恒娜, 顾秀瑛, 张思维, 等. 全球恶性肿瘤发病年龄分析[J]. 中华肿瘤杂志, 2018, 40(7): 543-549. doi: 10.3760/cma.j.issn.0253-3766.2018.07.012
[2]	袁建伟, 王保振, 耿北, 等. 经肛内外括约肌间切除术治疗低位直肠癌的术后肿瘤学效果及其影响因素[J]. 实用癌症杂志, 2018, 33(6): 982-984, 988. doi: 10.3969/j.issn.1001-5930.2018.06.034
[3]	刘启志, 楼征, 高显华, 等. 直肠癌患者术后生存与复发的临床病理因素探讨[J]. 中华普通外科杂志, 2017, 32(1): 5-8. doi: 10.3760/cma.j.issn.1007-631X.2017.01.003
[4]	Sasaki T, Ito Y, Ohue M, et al. Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase Ⅱ Clinical Trial[J]. Diseases of the Colon & Rectum, 2017, 60(9): 914-921. http://smartsearch.nstl.gov.cn/paper_detail.html?id=3ed1818fa8e6821605b6f93349343e48
[5]	Hida K, Okamura R, Park S Y, et al. A New Prediction Model for Local Recurrence After Curative Rectal Cancer Surgery: evelopment and Validation as an Asian Collaborative Study[J]. Diseases of the Colon & Rectum, 2017, 60(11): 1168-1174.
[6]	Gollins S, West N, Sebag-Montefiore D, et al. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: Significance of pre-treatment and post-resection RAS mutations[J]. British Journal of Cancer, 2017, 117(9): 1286-1294. doi: 10.1038/bjc.2017.294
[7]	Nishimura J, Hasegawa J, Kato T, et al. Phase Ⅱ trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer[J]. Cancer Chemotherapy and Pharmacology, 2018, 82(5): 13-17. http://www.sciencedirect.com/science/article/pii/S0923753419430652
[8]	刘荫华, 徐玲. 第七版《AJCC肿瘤分期手册》结直肠癌内容的更新与解读[J]. 中华胃肠外科杂志, 2010, 13(8): 629-631. doi: 10.3760/cma.j.issn.1671-0274.2010.08.028
[9]	Mch R A S, Swaminathan R, Mch A S. Laparoscopic versus open surgery for rectal cancer after neoadjuvant chemoradiation: Long‐term outcomes of a propensity score matched study[J]. Journal of Surgical Oncology, 2017, 117(3): 26-30. http://europepmc.org/abstract/MED/29044538
[10]	禹汇川, 骆衍新, 王小琳, 等. 直肠癌根治术后的复发类型对复发后远期生存的影响[J]. 中华医学杂志, 2016, 96(8): 625-628. doi: 10.3760/cma.j.issn.0376-2491.2016.08.009
[11]	朱立波, 李雪, 王荣, 等. 基于复发类型的Cox风险模型评估直肠癌根治术后复发患者预后的价值[J]. 现代消化及介入诊疗, 2018, 23(4): 476-478. . doi: 10.3969/j.issn.1672-2159.2018.04.013
[12]	Jang J K, Lee J L, Park S H, et al. Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer. [J]. British Journal of Surgery, 2018, 105(12): 1671-1679. doi: 10.1002/bjs.10898
[13]	李雨鑫, 王文玲, 董洪敏, 等. 局部进展期直肠癌根治术后卡培他滨+奥沙利铂同步放化疗的临床研究[J]. 贵州医药, 2017, 41(6): 647-649. doi: 10.3969/j.issn.1000-744X.2017.06.041
[14]	Jootun N, Evans T, Mak J, et al. Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment[J]. ANZ J Surg, 2018, 88(1/2): 62-65. doi: 10.1111/ans.14192/full
[15]	Jootun N, Evans T, Mak J, et al. Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment[J]. Anz Journal of Surgery, 2017, 88(1/2): 14-18. doi: 10.1111/ans.14192/full
[16]	Lee S Y, Chang H K, Kim Y J, et al. Prognostic significance of the distribution of lymph node metastasis in rectal cancer after neoadjuvant chemoradiation[J]. Journal of Surgical Oncology, 2017, 117(3): 23-25. http://www.researchgate.net/publication/320801246_Prognostic_significance_of_the_distribution_of_lymph_node_metastasis_in_rectal_cancer_after_neoadjuvant_chemoradiation

Cited By

Cited by

Periodical cited type(13)

1.	韩洁，伍丽，余敏. 基于“以通为补”理论探讨变应性鼻炎的治疗思路. 四川中医. 2024(04): 63-67 .
2.	王伊娜，张崧，胡志佳. 杏苏饮联合揿针对变应性鼻炎合并支气管哮喘患儿的临床疗效及对免疫平衡、血清IL-37和IL-27水平的影响. 中国医院用药评价与分析. 2024(11): 1313-1317 .
3.	俞琳，潘辉，洪开听，占焕平，陈萍，王烨凯. 外周血血小板计数血小板分布宽度血小板平均体积及Th1/Th2细胞比值与支气管哮喘合并感染患儿病情变化的关系. 中国妇幼保健. 2022(01): 65-67 .
4.	林爽，陈丽萍. 益生菌治疗支气管哮喘的疗效分析. 中外医疗. 2021(19): 17-20 .
5.	何玮，胡敏，梁兴明，赵世杰，唐军，杨强威，林华国，蓝英，陈龙. 外周血辅助性T细胞9细胞因子与过敏性鼻炎患者疾病严重程度的相关性. 广西医学. 2021(14): 1691-1694 .
6.	施乐，吴建萍，王树霞，陈伟斌. “肺鼻同治”法治疗儿童变应性鼻炎合并哮喘的研究进展. 现代中西医结合杂志. 2020(17): 1930-1935 .
7.	蔡珍珍，周玲，潘静，李功璐，张慧. 哮喘患儿RSV和IFV感染与CD4~+T细胞亚群相关性研究. 医学动物防制. 2020(08): 747-750 .
8.	张炜伟，冯波. 布地奈德辅助治疗老年过敏性鼻炎效果观察及对免疫因子的影响. 中国乡村医药. 2020(12): 15-16 .
9.	谭燕萍，李景新，欧晓华，陈锡传. 益生菌联合孟鲁司特钠咀嚼片对支气管哮喘伴变应性鼻炎患儿外周血Th_(17)/Treg免疫平衡的影响. 中国药业. 2019(15): 64-67 .
10.	李萌，王亚晶，孟桓申. 消风通窍法治疗小儿过敏性鼻炎临床疗效及安全性分析. 湖北中医药大学学报. 2019(06): 80-82 .
11.	张杨，王珍，王大斌，罗四维，梁耕田. 变应性鼻炎合并哮喘患者外周血Th17、Treg、白细胞介素、黏附因子及可溶性E选择素的水平及其临床意义. 中国耳鼻咽喉头颈外科. 2018(08): 453-454 .
12.	吕平，彭万胜，董淮富. 新型抑制性细胞因子IL-35与支气管哮喘的研究进展. 中国临床药理学与治疗学. 2018(02): 230-234 .
13.	霍蓓蓓. 变应性鼻炎与支气管哮喘临床表现的相关性. 包头医学院学报. 2018(12): 55-56 .

Other cited types(5)

Get Citation

PDF

XML

Article views (202) PDF downloads (5) Cited by(18)

Turn off MathJax

Article Contents

Abstract

References

Clinical effect of preoperative concurrent chemoradiotherapy with oxaliplatin and capecitabine in treatment of patients with medium to advanced rectal cancer

Abstract

References

Cited by

Periodical cited type(13)

Other cited types(5)

Catalog

Export File

Citation

Format

Content